Integral Health Asset Management, LLC Alkermes Plc. Transaction History

Integral Health Asset Management, LLC

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$26.4 - $32.56 $26,400 - $32,560	1,000 Added 0.4%	250,000 $6.77 Million
Q4 2023 Feb 14, 2024	SELL	$23.37 - $28.68 $607,620 - $745,680	-26,000 Reduced 9.45%	249,000 $6.91 Million
Q3 2023 Nov 14, 2023	SELL	$27.17 - $31.97 $244,530 - $287,730	-9,000 Reduced 3.17%	275,000 $7.7 Million
Q2 2023 Aug 11, 2023	BUY	$28.34 - $33.63 $2.98 Million - $3.53 Million	105,000 Added 58.66%	284,000 $8.89 Million
Q1 2023 May 09, 2023	BUY	$25.31 - $29.02 $4.53 Million - $5.19 Million	179,000 New	179,000 $5.05 Million
Q3 2022 Nov 14, 2022	SELL	$22.0 - $31.87 $1.36 Million - $1.97 Million	-61,966 Reduced 23.65%	200,000 $4.47 Million
Q2 2022 Aug 03, 2022	BUY	$26.4 - $30.54 $315,902 - $365,441	11,966 Added 4.79%	261,966 $7.8 Million
Q1 2022 May 12, 2022	BUY	$23.07 - $27.99 $4.61 Million - $5.6 Million	200,000 Added 400.0%	250,000 $6.58 Million
Q4 2021 Feb 02, 2022	BUY	$21.47 - $32.08 $1.07 Million - $1.6 Million	50,000 New	50,000 $1.16 Million
Q3 2021 Nov 12, 2021	SELL	$23.37 - $32.13 $3.51 Million - $4.82 Million	-150,000 Closed	0 $0
Q2 2021 Aug 30, 2021	SELL	$18.78 - $25.15 $2.82 Million - $3.77 Million	-150,000 Reduced 50.0%	150,000 $3.68 Million
Q2 2021 Aug 13, 2021	BUY	$18.78 - $25.15 $5.63 Million - $7.55 Million	300,000 New	300,000 $7.36 Million
Q2 2020 Aug 14, 2020	SELL	$13.31 - $19.41 $2 Million - $2.91 Million	-150,000 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$13.06 - $21.24 $1.96 Million - $3.19 Million	150,000 New	150,000 $2.16 Million

361

181M

175K

96.6K

Ticker ALKS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 164,254,000
Market Cap $4.73B
Description
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...

Get notified when there are updates to the investment portfolio of Integral Health Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Integral Health Asset Management, LLC with notifications on news.